Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $1.45M invested in Proshares UltraPro NASDAQ Biotechnology in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1% more capital invested
Capital invested by funds: $1.43M → $1.45M (+$19K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$372K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$328K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$244K |
| 2 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
-$209K |
| 3 |
Jane Street
New York
|
-$189K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $553K | -$189K | -7,641 | -26% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $407K | +$328K | +13,275 | +540% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $391K | +$372K | +15,074 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $57K | +$54K | +2,190 | New |
|
5
Morgan Stanley
New York
| $21K | – | – | – |
|
|
LTFS
6
Ladenburg Thalmann Financial Services
Miami,
Florida
| $19K | – | – | – |
|
|
VF
7
Virtu Financial
New York
| – | -$244K | -8,328 | Closed |
|
|
EWA
8
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
| – | -$209K | -7,125 | Closed |
|
|
9
Simplex Trading
Chicago,
Illinois
| – | -$9K | -315 | Closed |
|
UBIO Hedge Fund Activity: Q2 2019 in Review
6 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q2 2019, worth a combined $1.45M — up 1.3% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of UBIO and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $372K. The largest seller was Virtu Financial, exiting entirely with an estimated $244K sold.
- 6 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q2 2019, down from 7 in Q1 2019.
- Funds reported $1.45M of Proshares UltraPro NASDAQ Biotechnology stock for Q2 2019, up 1.3% quarter-over-quarter.
- 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q2 2019 was Susquehanna International Group, an estimated $372K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q2 2019 was Virtu Financial, an estimated $244K sold.
Based on aggregated 13F filings for Q2 2019.